DEERFIELD, Ill., November 09, 2015 - Walgreens Boots Alliance, Inc. (Nasdaq: WBA) Executive Vice President and President of Walgreen Co. Alex Gourlay will present during the Credit Suisse 2015 Healthcare Conference at the Phoenician resort, Scottsdale, Ariz., at approximately 10 a.m. Mountain time (Noon Eastern standard time) Tuesday, 10 November.
Gourlay’s presentation will be webcast live and can be heard by visiting http://investor.walgreensbootsalliance.com.
Notes to Editors:
About Walgreens Boots Alliance
Walgreens Boots Alliance (Nasdaq: WBA) is the first global pharmacy-led, health and wellbeing enterprise.
The company was created through the combination of Walgreens and Alliance Boots in December 2014, bringing together two leading companies with iconic brands, complementary geographic footprints, shared values and a heritage of trusted health care services through pharmaceutical wholesaling and community pharmacy care, dating back more than 100 years.
The company employs more than 370,000* people and has a presence in more than 25* countries; it is the largest retail pharmacy, health and daily living destination in the USA and Europe. Including its equity method investments, Walgreens Boots Alliance is a global leader in pharmacy-led, health and wellbeing retail with over 13,100* stores in 11* countries. The company includes one of the largest global pharmaceutical wholesale and distribution networks with over 350* distribution centers delivering to more than 200,000** pharmacies, doctors, health centers and hospitals each year in 19* countries. In addition, Walgreens Boots Alliance is one of the world’s largest purchasers of prescription drugs and many other health and wellbeing products.
Its portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as increasingly global health and beauty product brands, such as No7, Botanics, Liz Earle and Soap & Glory. More company information is available at www.walgreensbootsalliance.com.
* As at 31 August 2015 including equity method investments
** For 12 months ended 31 August 2015 including equity method investments